文献速递免疫规划妇幼与学校卫生

母亲接种百白破疫苗对幼儿百日咳加强免疫应答的影响:随机试验随访

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
PubMed 文献 · Vaccine · 2021-02-19

本研究是对一项IV期随机对照试验的随访,评估孕期接种Tdap疫苗所诱导的经胎盘抗体是否持续干扰幼儿加强免疫应答。263名Tdap组和277名对照组幼儿在11-18月龄接种DTaP-HepB-IPV/Hib加强针,加强前对照组百日咳抗原和破伤风抗体GMC为Tdap组的1.4-1.5倍;加强后两组百日咳抗原应答率≥92.1%,其他抗原血清保护率≥99.2%。加强后对照组抗FHA、抗PT和抗白喉GMC仍高于Tdap组。

要点

  • 孕期接种Tdap后,幼儿加强前百日咳抗体浓度仍低于对照组。
  • 加强接种后两组百日咳抗原应答率≥92.1%,其他抗原血清保护率≥99.2%。
  • 加强后抗FHA和抗PT抗体浓度仍较低,但抗pertactin无差异。

核心结论

  • 母亲接种Tdap所诱导的抗体干扰导致幼儿加强前百日咳抗体浓度较低,加强后抗FHA和抗PT抗体浓度仍较低,但抗pertactin无差异,其临床意义需进一步评估。

研究设计与样本

  • 一项IV期、观察者盲、安慰剂对照随机试验(NCT02377349)的随访研究,孕妇在澳大利亚、加拿大和欧洲随机接种Tdap疫苗或安慰剂,其婴儿完成基础免疫后,在11-18月龄接种DTaP-HepB-IPV/Hib和13价肺炎球菌结合疫苗加强针。
  • 本次分析纳入263名Tdap组和277名对照组幼儿,描述性评估加强前后免疫原性及加强针反应原性和安全性。

主要发现

  • 加强前,对照组三种百日咳抗原和破伤风的观察GMC为Tdap组的1.4-1.5倍,其他DTaP-HepB-IPV/Hib抗原无差异。
  • 加强后1个月,两组百日咳抗原加强应答率≥92.1%,其他抗原血清保护率≥99.2%。
  • 加强后,对照组抗FHA、抗PT和抗白喉GMC分别约为Tdap组的1.2倍、1.5倍和1.4倍,其他抗原GMC两组相似。
  • 对照组报告3例严重不良事件(与接种无关),Tdap组加强前发生1例死亡(与接种无关)。

关键数值与推荐

  • 加强后1个月百日咳抗原加强应答率≥92.1%,其他DTaP-HepB-IPV/Hib抗原血清保护率≥99.2%(两组均达到主要目标)。

临床怎么用

  • 孕期Tdap接种后,幼儿加强前百日咳抗体浓度较低,但加强后仍能达到高应答率和血清保护率,支持按程序加强接种。
  • 对母亲孕期接种Tdap的幼儿,应关注加强后抗FHA和抗PT抗体浓度较低的现象,但其临床意义尚需进一步研究。

局限性

  • 免疫原性、反应原性和安全性分析为描述性,未进行正式统计学比较。
  • 随访至加强后1个月,未评估长期抗体持久性和临床保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transplacentally transferred antibodies induced by maternal pertussis vaccination interfere with infant immune responses to pertussis primary vaccination. We evaluated whether this interference remains in toddlers after booster vaccination. METHODS: In a prior phase IV, observer-blind, placebo-controlled, randomized study (NCT02377349), pregnant women in Australia, Canada and Europe received intramuscular tetanus-reduced-antigen-content diphtheria-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) at 270/7-366/7 weeks' gestation, with crossover immunization postpartum. Their infants were primed (study NCT02422264) and boosted (at 11-18 months; current study NCT02853929) with diphtheria-tetanus-three-component acellular pertussis-hepatitis B virus-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTaP-HepB-IPV/Hib) and 13-valent pneumococcal conjugate vaccine. Immunogenicity before and after booster vaccination, and reactogenicity and safety of the booster were evaluated descriptively. RESULTS: 263 (Tdap group) and 277 (control group) toddlers received a DTaP-HepB-IPV/Hib booster. Pre-booster vaccination, observed geometric mean concentrations (GMCs) for the three pertussis antigens and diphtheria were 1.4-1.5-fold higher in controls than in the Tdap group. No differences were observed for the other DTaP-HepB-IPV/Hib antigens. One month post-booster vaccination, booster response rates for pertussis antigens were ≥ 92.1% and seroprotection rates for the other DTaP-HepB-IPV/Hib antigens were ≥ 99.2% in both groups (primary objective). Higher post-booster GMCs were observed in controls versus the Tdap group for anti-filamentous hemagglutinin (1.2-fold), anti-pertussis toxoid (1.5-fold) and anti-diphtheria (1.4-fold). GMCs for the other DTaP-HepB-IPV/Hib antigens were similar between groups. Serious adverse events were reported for three toddlers (controls, not vaccination-related). One death occurred pre-booster (Tdap group, not vaccination-related). CONCLUSIONS: As a consequence of interference of maternal pertussis antibodies with infant immune responses to pertussis primary vaccination, pertussis antibody concentrations were still lower in toddlers from Tdap-vaccinated mothers before DTaP-HepB-IPV/Hib booster vaccination. After the booster, antibody concentrations were lower for filamentous hemagglutinin and pertussis toxoid but not for pertactin. The clinical significance of this interference requires further evaluation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02853929.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martinón-Torres F, Halperin SA, Nolan T, et al. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial. Vaccine. 2021. PMID: 33612341. doi:10.1016/j.vaccine.2021.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。